Health knowledge made personal
Join this community!
› Share page: Email Digg del.icio.us Reddit icon StumbleUpon Technorati
Go
Search posts:

Antitumor Immunity Elicited by Defensin-Tumor Antigen Fusions

Posted Jun 14 2010 5:00pm

Description of Invention:
Tumor antigens are known to be poorly immunogenic and attempts to elicit immune responses against the epitopes of antigens specific to tumor cells have been largely unsuccessful. The inventors have developed a cancer vaccine comprising a defensin fused to a tumor antigen or viral antigen to enhance the immunogenicity of the tumor antigen or viral antigen. The inventors have demonstrated, with animal data, that chimeric proteins, comprising a defensin fused to a model tumor antigen (lymphoma-derived single-chain Fv), when administered to a subject, generate a measurable humoral and anti-tumor cellular immune response.

Inventors:
Arya Biragyn (NCI)
Larry W Kwak (NCI)


Patent Status:
HHS, Reference No. E-196-2000/0
US, Application No. 10/380,926 filed 17 Mar 2003
US, Application No. 12/786,334 filed 24 May 2010



Portfolios:
Cancer
Cancer - Therapeutics
In-vivo Data



For Additional Information Please Contact:
Patrick McCue Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: McCuepat@mail.nih.gov
Phone: 301-496-7057
Fax: 301-402-0220


Ref No: 175

Updated: 06/2010

Post a comment
Write a comment:

Related Searches